Related Experiment Video

Updated: Apr 25, 2026

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

2.1K

Genetic associations and functional characterization of M1 aminopeptidases and immune-mediated diseases

N Agrawal1, M A Brown1

  • 1University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.

Genes and Immunity
|August 22, 2014
PubMed

Insights

Endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) and NPEPPS are crucial for immune peptide processing. Genetic links between these enzymes and immune-mediated diseases highlight their therapeutic potential.

Area of Science:

  • Biochemistry
  • Immunology
  • Genetics

Background:

  • Endoplasmic reticulum aminopeptidase 1 (ERAP1), ERAP2, and puromycin-sensitive aminopeptidase (NPEPPS) are M1 family zinc metallopeptidases.
  • These enzymes are vital for processing peptides for presentation on MHC Class I molecules.

Purpose of the Study:

  • To review the genetic associations of ERAP1, ERAP2, and NPEPPS with immune-mediated diseases.
  • To explore the functional roles of these aminopeptidases in disease pathogenesis.
  • To discuss their potential as therapeutic targets.

Main Methods:

  • Review of genome-wide association studies (GWAS).
  • Analysis of genetic interactions between aminopeptidases and HLA Class I loci.
  • Synthesis of current understanding of enzyme function in disease.

Main Results:

  • GWAS have linked ERAP1, ERAP2, and NPEPPS to diseases including ankylosing spondylitis, psoriasis, Behçet's disease, inflammatory bowel disease, and type I diabetes.
  • Significant genetic interactions exist between these aminopeptidases and associated HLA Class I loci.
  • These enzymes play a critical role in the immune system's peptide processing pathway.

Conclusions:

  • ERAP1, ERAP2, and NPEPPS are strongly associated with immune-mediated diseases.
  • Understanding their genetic associations and functional roles is key to developing new therapies.
  • Targeting these aminopeptidases offers a promising therapeutic strategy for various immune disorders.

More Related Videos

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

15.1K
Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

6.6K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156